Clinical Trial Update: Fecal Microbiota Transplant (FMT) Plus Fidaxomicin for Severe or Fulminant Clostridium Difficile Infection [Phase 2]

View source ↗

Summary

Phase 2 trial of fecal microbiota transplant plus fidaxomicin for severe or fulminant Clostridium difficile infection has been terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Clostridium Difficile Infection

Drugs mentioned

• Fecal microbiota transplant (fecal microbiota transplant)
• Fidaxomicin (fidaxomicin)

Snippet

Sponsor: University of Alberta | Conditions: Clostridium Difficile | Phase 2 | Status: TERMINATED | Results posted: 2022-12-13